EMEA (Europe, Middle East and Africa) Multiple Sclerosis (MS) Drugs Market Report 2017

December 2017 | 111 pages | ID: EA38E17FAD7EN
QYResearch

Abstracts

In this report, the EMEA Multiple Sclerosis (MS) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Multiple Sclerosis (MS) Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Multiple Sclerosis (MS) Drugs market competition by top manufacturers/players, with Multiple Sclerosis (MS) Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Bayer AG
• Bayhill Therapeutics
• Biogen Idec
• Cinnagen
• Daiichi Sankyo
• Eli Lilly
• Fast Forward Llc
• Antisense Therapeutics
• Apitope
• Five Prime Therapeutics
• Genmab
• Artielle Immunotherapeutics
• Genzyme
• Glaxosmithkline
• Gw Pharmaceuticals
• Innate Immunotherapeutics

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Copaxone (Glatiramer Acetate, Copolymer 1)
• Novantrone (Mitoxantrone)
• Gilenya (Fingolimod, Fty720)
• Aubagio (Teriflunomide)
• Tecfidera (Dimethyl Fumarate)
• Firategrast (Sb683699, T-0047)
• Siponimod (Baf312)
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• RRMS
• SPMS
• PPMS
• PRMS

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Multiple Sclerosis (MS) Drugs Market Report 2017

1 MULTIPLE SCLEROSIS (MS) DRUGS OVERVIEW

1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
1.2 Classification of Multiple Sclerosis (MS) Drugs
  1.2.1 EMEA Multiple Sclerosis (MS) Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Multiple Sclerosis (MS) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Copaxone (Glatiramer Acetate, Copolymer 1)
  1.2.4 Novantrone (Mitoxantrone)
  1.2.5 Gilenya (Fingolimod, Fty720)
  1.2.6 Aubagio (Teriflunomide)
  1.2.7 Tecfidera (Dimethyl Fumarate)
  1.2.8 Firategrast (Sb683699, T-0047)
  1.2.9 Siponimod (Baf312)
  1.2.10 Others
1.3 EMEA Multiple Sclerosis (MS) Drugs Market by Application/End Users
  1.3.1 EMEA Multiple Sclerosis (MS) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 RRMS
  1.3.3 SPMS
  1.3.4 PPMS
  1.3.5 PRMS
1.4 EMEA Multiple Sclerosis (MS) Drugs Market by Region
  1.4.1 EMEA Multiple Sclerosis (MS) Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Multiple Sclerosis (MS) Drugs (2012-2022)
  1.5.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012-2022)

2 EMEA MULTIPLE SCLEROSIS (MS) DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Multiple Sclerosis (MS) Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Multiple Sclerosis (MS) Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Multiple Sclerosis (MS) Drugs Sale Price by Players (2012-2017)
2.2 EMEA Multiple Sclerosis (MS) Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Multiple Sclerosis (MS) Drugs Sale Price by Type (2012-2017)
2.3 EMEA Multiple Sclerosis (MS) Drugs (Volume) by Application
2.4 EMEA Multiple Sclerosis (MS) Drugs (Volume and Value) by Region
  2.4.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Multiple Sclerosis (MS) Drugs Sales Price by Region (2012-2017)

3 EUROPE MULTIPLE SCLEROSIS (MS) DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Multiple Sclerosis (MS) Drugs Sales and Value (2012-2017)
  3.1.1 Europe Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Multiple Sclerosis (MS) Drugs Sales and Market Share by Type
3.3 Europe Multiple Sclerosis (MS) Drugs Sales and Market Share by Application
3.4 Europe Multiple Sclerosis (MS) Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Multiple Sclerosis (MS) Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST MULTIPLE SCLEROSIS (MS) DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Multiple Sclerosis (MS) Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Multiple Sclerosis (MS) Drugs Sales and Market Share by Type
4.3 Middle East Multiple Sclerosis (MS) Drugs Sales and Market Share by Application
4.4 Middle East Multiple Sclerosis (MS) Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Multiple Sclerosis (MS) Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Multiple Sclerosis (MS) Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)

5 AFRICA MULTIPLE SCLEROSIS (MS) DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Multiple Sclerosis (MS) Drugs Sales and Value (2012-2017)
  5.1.1 Africa Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Multiple Sclerosis (MS) Drugs Sales and Market Share by Type
5.3 Africa Multiple Sclerosis (MS) Drugs Sales and Market Share by Application
5.4 Africa Multiple Sclerosis (MS) Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Multiple Sclerosis (MS) Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Multiple Sclerosis (MS) Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2017)

6 EMEA MULTIPLE SCLEROSIS (MS) DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Bayer AG
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bayhill Therapeutics
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Biogen Idec
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Cinnagen
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Daiichi Sankyo
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Eli Lilly
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Fast Forward Llc
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Antisense Therapeutics
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Apitope
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Five Prime Therapeutics
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Genmab
6.12 Artielle Immunotherapeutics
6.13 Genzyme
6.14 Glaxosmithkline
6.15 Gw Pharmaceuticals
6.16 Innate Immunotherapeutics

7 MULTIPLE SCLEROSIS (MS) DRUGS MANUFACTURING COST ANALYSIS

7.1 Multiple Sclerosis (MS) Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA MULTIPLE SCLEROSIS (MS) DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Multiple Sclerosis (MS) Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Multiple Sclerosis (MS) Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Multiple Sclerosis (MS) Drugs
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) by Type (2012-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Copaxone (Glatiramer Acetate, Copolymer 1) Product Picture
Figure Novantrone (Mitoxantrone) Product Picture
Figure Gilenya (Fingolimod, Fty720) Product Picture
Figure Aubagio (Teriflunomide) Product Picture
Figure Tecfidera (Dimethyl Fumarate) Product Picture
Figure Firategrast (Sb683699, T-0047) Product Picture
Figure Siponimod (Baf312) Product Picture
Figure Others Product Picture
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) by Application (2012-2022)
Figure EMEA Sales Market Share of Multiple Sclerosis (MS) Drugs by Application in 2016
Figure RRMS Examples
Table Key Downstream Customer in RRMS
Figure SPMS Examples
Table Key Downstream Customer in SPMS
Figure PPMS Examples
Table Key Downstream Customer in PPMS
Figure PRMS Examples
Table Key Downstream Customer in PRMS
Figure EMEA Multiple Sclerosis (MS) Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Multiple Sclerosis (MS) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Multiple Sclerosis (MS) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) of Major Players (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Sales Share by Players (2012-2017)
Figure 2016 Multiple Sclerosis (MS) Drugs Sales Share by Players
Figure 2017 Multiple Sclerosis (MS) Drugs Sales Share by Players
Figure EMEA Multiple Sclerosis (MS) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Multiple Sclerosis (MS) Drugs Revenue Share by Players
Table 2017 EMEA Multiple Sclerosis (MS) Drugs Revenue Share by Players
Table EMEA Multiple Sclerosis (MS) Drugs Sale Price (USD/Pcs) by Players (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Market Share by Type (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Multiple Sclerosis (MS) Drugs by Type (2012-2017)
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Multiple Sclerosis (MS) Drugs by Type in 2016
Table EMEA Multiple Sclerosis (MS) Drugs Sale Price (USD/Pcs) by Type (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Multiple Sclerosis (MS) Drugs by Application (2012-2017)
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2016
Table EMEA Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Multiple Sclerosis (MS) Drugs by Region (2012-2017)
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Market Share in 2016
Table EMEA Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Multiple Sclerosis (MS) Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Multiple Sclerosis (MS) Drugs by Region (2012-2017)
Figure EMEA Multiple Sclerosis (MS) Drugs Revenue Market Share Regions in 2016
Table EMEA Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs) by Region (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012-2017)
Table Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2012-2017)
Table Europe Multiple Sclerosis (MS) Drugs Market Share by Type (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Market Share by Type in 2016
Table Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2012-2017)
Table Europe Multiple Sclerosis (MS) Drugs Market Share by Application (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Market Share by Application in 2016
Table Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Countries (2012-2017)
Table Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Countries in 2016
Table Europe Multiple Sclerosis (MS) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries in 2016
Figure Germany Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure France Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UK Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Russia Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Italy Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Benelux Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2012-2017)
Table Middle East Multiple Sclerosis (MS) Drugs Market Share by Type (2012-2017)
Figure Middle East Multiple Sclerosis (MS) Drugs Market Share by Type (2012-2017)
Table Middle East Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Applications (2012-2017)
Table Middle East Multiple Sclerosis (MS) Drugs Market Share by Applications (2012-2017)
Figure Middle East Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2016
Table Middle East Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Middle East Multiple Sclerosis (MS) Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Multiple Sclerosis (MS) Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Multiple Sclerosis (MS) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Israel Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UAE Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Iran Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2012-2017)
Table Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2016
Table Africa Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2012-2017)
Table Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2012-2017)
Table Africa Multiple Sclerosis (MS) Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Countries in 2016
Table Africa Multiple Sclerosis (MS) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries in 2016
Figure South Africa Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Nigeria Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Egypt Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Algeria Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Table Bayer AG Multiple Sclerosis (MS) Drugs Basic Information List
Table Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Basic Information List
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Biogen Idec Multiple Sclerosis (MS) Drugs Basic Information List
Table Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Cinnagen Multiple Sclerosis (MS) Drugs Basic Information List
Table Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Basic Information List
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Eli Lilly Multiple Sclerosis (MS) Drugs Basic Information List
Table Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Basic Information List
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Basic Information List
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Apitope Multiple Sclerosis (MS) Drugs Basic Information List
Table Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Apitope Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Apitope Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Basic Information List
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales Market Share in EMEA (2012-2017)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share in EMEA (2012-2017)
Table Genmab Multiple Sclerosis (MS) Drugs Basic Information List
Table Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Basic Information List
Table Genzyme Multiple Sclerosis (MS) Drugs Basic Information List
Table Glaxosmithkline Multiple Sclerosis (MS) Drugs Basic Information List
Table Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Basic Information List
Table Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Multiple Sclerosis (MS) Drugs
Figure Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
Table Raw Materials Sources of Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
Table Major Buyers of Multiple Sclerosis (MS) Drugs
Table Distributors/Traders List
Figure EMEA Multiple Sclerosis (MS) Drugs Sales (K Pcs) and Growth Rate Forecast (2017-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Price (USD/Pcs) and Trend Forecast (2017-2022)
Table EMEA Multiple Sclerosis (MS) Drugs Sales (K Pcs) Forecast by Region (2017-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Multiple Sclerosis (MS) Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Multiple Sclerosis (MS) Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Europe Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Multiple Sclerosis (MS) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Multiple Sclerosis (MS) Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Middle East Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Multiple Sclerosis (MS) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Multiple Sclerosis (MS) Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Africa Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Multiple Sclerosis (MS) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Multiple Sclerosis (MS) Drugs Sales (K Pcs) Forecast by Type (2017-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Multiple Sclerosis (MS) Drugs Sales (K Pcs) Forecast by Application (2017-2022)
Figure EMEA Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources